Patent: 10,130,697
✉ Email this page to a colleague
Summary for Patent: 10,130,697
Title: | Vaccines comprising mutant attenuated influenza viruses |
Abstract: | The invention provides a vaccine comprising an effective amount of an isolated recombinant influenza virus comprising a mutant M gene segment that is mutated so that upon viral replication the mutant M gene expresses a functional M1 protein and a mutant M2 protein with a deletion of the cytoplasmic tail and either lacking a transmembrane domain or having a mutated transmembrane domain. |
Inventor(s): | Watanabe; Shinji (Madison, WI), Watanabe; Tokiko (Madison, WI), Kawaoka; Yoshihiro (Middleton, WI) |
Assignee: | Wisconsin Alumni Research Foundation (WARF) (Madison, WI) |
Application Number: | 13/070,110 |
Patent Claims: | see list of patent claims |
Details for Patent 10,130,697
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Seqirus Vaccines Limited | FLUVIRIN | influenza virus vaccine | Injection | 103837 | 11/03/1998 | ⤷ Try a Trial | 2030-03-23 |
Sanofi Pasteur Inc. | FLUZONE, FLUZONE HD QUADRIVALENT, FLUZONE HIGH DOSE, FLUZONE INTRADERMAL, FLUZONE QUADRIVALENT | influenza virus vaccine | Injection | 103914 | 12/09/1999 | ⤷ Try a Trial | 2030-03-23 |
Sanofi Pasteur Inc. | FLUZONE, FLUZONE HD QUADRIVALENT, FLUZONE HIGH DOSE, FLUZONE INTRADERMAL, FLUZONE QUADRIVALENT | influenza virus vaccine | Injection | 103914 | 12/23/1909 | ⤷ Try a Trial | 2030-03-23 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |